A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07223047
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Malignancies
  • Colorectal Cancer (CRC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986523 — DRUG
    Specified dose on specified days
  • Gemcitabine — DRUG
    Specified dose on specified days
  • Nab-Paclitaxel — DRUG
    Specified dose on specified days
  • Cetuximab — DRUG
    Specified dose on specified days
  • Pembrolizumab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Key Dates

Start date
Nov 25, 2025
Status verified
May 2026
Primary completion
Oct 13, 2028
Completion
Oct 13, 2028

Study Design

Enrollment
252 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Experimental: Arm B
  • Experimental: Arm C
  • Experimental: Arm D
  • Experimental: Arm E
  • Experimental: Arm F

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 3 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (4)

FacilityCityStateZIPSite coordinators
Johns Hopkins HospitalBaltimoreMaryland21287
Nilofer Azad, Site 0009
410-502-2995
NEXT OncologySan AntonioTexas78229
David Sommerhalder, Site 0001
210-580-9500
START Mountain RegionWest Valley CityUtah84119
Justin Call, Site 0007
801-907-4750
NEXT VirginiaFairfaxVirginia22031
Alexander Spira, Site 0011
703-280-5390

Find similar trials in Baltimore, MD

By research site
Johns Hopkins Hospital· Baltimore, MDNEXT Oncology· San Antonio, TXSTART Mountain Region· West Valley City, UTNEXT Virginia· Fairfax, VA

Related Studies